Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% (Cuvitru) in Japanese PID
NCT04346108Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Takeda. Started Aug 2020; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT04346108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346108.